-
Eli Lilly and Company announced an agreement with Hims & Hers Health to offer FDA-approved obesity drugs Zepbound and Foundayo on the Hims & Hers platform, giving eligible telehealth patients access to Lilly's self-pay prices without leaving the service.
-
The collaboration shifts Hims & Hers weight loss offering fully to branded GLP-1 therapies, removes compounded copies from its model, and ties its telehealth engine directly to a major drugmaker's obesity portfolio and pricing.
-
This development examines how Hims & Hers Health's investment narrative is reshaped by integrating Lilly's GLP-1 pricing and fulfillment into its platform.
See how the Hims & Hers Health news fits into a wider telehealth and consumer-health opportunity by reviewing our hand-picked 19 high quality undiscovered gems that are building similar recurring-care models.
Hims & Hers Health Investment Narrative Recap
To own Hims & Hers Health, you need to believe its telehealth subscription engine can turn interest in higher complexity care, like GLP 1 weight loss, into long term, profitable patient relationships. The Lilly deal directly plugs branded obesity drugs into that system, which could support subscriber depth but may lean further into lower gross margin categories.
The key near term swing factor is whether GLP 1 driven programs and AI automation can offset continued cash needs and margin pressure. The biggest risk remains external scrutiny on billing, privacy, and payments. This new agreement does not remove that overhang and may even increase operational visibility with regulators and processors.
The Eli Lilly partnership sits alongside Hims & Hers Health's build out of its Hims & Hers Benefits ecosystem. In this ecosystem, partners like Grüns, Medjet, Tonal, and Viome extend support across nutrition, fitness, and emergency medical transport. That broader bundle points to a recurring care thesis built on multiple touchpoints around each subscriber.
For catalysts, this matters because GLP 1 weight loss, testosterone, and other chronic treatments rely on retention and engagement rather than one off prescriptions. A richer benefits program could help keep almost 3 million subscribers inside the platform while the firm pushes AI, pharmacy infrastructure, and international operations to improve efficiency and absorb regulatory and payment related friction.
Hims & Hers Health's consensus narrative points to revenue of US$4.6b and earnings of US$235.7 million by 2029, built on analysts' assumption of 21.7% yearly revenue growth and an earnings swing of about US$377.7 million from a loss of US$142.0 million today.
Uncover how Hims & Hers Health's fair value indicates a 20% potential upside to its current price before the discount gap begins to close.
Exploring Other Perspectives
One alternate view focuses less on GLP 1 growth and more on regulatory and payments risk around Hims & Hers Health. The most cautious analysts were only penciling in about US$4.1b of 2029 revenue and US$163.7 million of earnings before this Eli Lilly deal. That is a far more conservative story. Use this new development as a prompt to compare those expectations with your own and to explore a full range of opinions.
Explore 16 other Hims & Hers Health fair value estimates , including one that suggests it could be worth just $25.70.
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
-
A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
-
See our latest analysis for Hims & Hers Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Hims & Hers Health's overall financial health at a glance.
Looking For More Hims & Hers Health Style Ideas?
If the Hims & Hers Health story has you thinking about other potential opportunities, it can help to scan a broader field of companies that share similar qualities like strong balance sheets, income potential, or overlooked fundamentals.
-
For investors who want resilient businesses that aim to limit downside risk, start with a curated set of 29 resilient stocks with low risk scores that score well on stability.
-
If reliable income is a priority, check out companies in the 8 dividend fortresses that focus on combining high yields with steadier cash flows.
-
To hunt for less crowded ideas with solid financial footing, filter for a 19 high quality undiscovered gems that are still off most investors' radar.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HIMS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
